Study guide
Arthritis, autoimmune disease and geriatric care
AMC CAT MCQ Examination AMC Part 1
Track your progress as you read
Finished sections get a check mark.
1 Acute Coronary Syndromes & ECG Localization
ACS recognition and ECG localisation Reperfusion and infarction complications
2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias
Heart failure assessment and treatment Arrhythmias and conduction emergencies
3 Systemic Hypertension & Peripheral Vascular Disease
Blood pressure and cardiovascular risk Secondary hypertension and arterial disease
4 Valvular Heart Disease, Infective Endocarditis & Pericarditis
Aortic and mitral valve disease Endocarditis and pericardial emergencies
5 Asthma & COPD Acute Flares and Maintenance
Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations
6 Pneumonia, pleural disease and respiratory failure
Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis
7 GI bleeding, bowel inflammation and malabsorption
GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS
8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis
Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance
9 Diabetes, thyroid and adrenal disease
Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease
10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies
AKI and chronic kidney disease Potassium and sodium emergencies
11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment
Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care
12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis
Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia
13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology
Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms
14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis
Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment
15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries
Trauma primary survey and adjuncts Chest trauma and immediate threats
16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance
Head injury, imaging and haemorrhage Herniation and spinal cord injury
17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome
Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury
18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care
Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus
19 Aortic Aneurysms & Acute Arterial Limb Ischaemia
Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia
20 Urological Emergencies, Testicular Torsion & Haematuria Investigation
Retention, stones and obstructed infection Scrotal pain and haematuria
21 Preoperative Risk Stratification & Postoperative Surgical Complications
Preoperative assessment and medicines Postoperative complications and prevention
22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening
Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons
23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy
Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding
24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies
Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth
25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis
Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care
26 Contraception, Emergency Contraception & Pregnancy Termination
Contraceptive choice and missed pills Emergency contraception and abortion
27 Australian Cervical Screening Program & Gynaecological Malignancies
Cervical screening and cervical cancer Endometrial and ovarian cancer
28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice
Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening
29 Developmental Milestones, Growth Charts & Failure to Thrive
Developmental milestones Regression, autism and support Faltering growth and developmental comparisons
30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions
Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons
31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis
Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis
32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease
Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up
33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury
Pyloric stenosis Intussusception and dehydration Child protection and injury assessment
34 The Mental State Examination & Suicide Risk Stratification
Mental state examination and psychotic symptoms Suicide formulation and mental health law
35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers
Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT
36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder
Anxiety, panic and agoraphobia OCD and trauma-related disorders
37 Schizophrenia, Acute Psychosis & Antipsychotic Management
Psychosis assessment and antipsychotics Clozapine and severe adverse effects
38 Substance Use Disorders & Acute Withdrawal Syndromes
Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants
39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry
Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry
40 Medicare, PBS, AHPRA & Good Medical Practice Framework
Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications
41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment
Consent, material risks and young people Capacity, refusal and substitute decisions
42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications
Privacy, disclosure and child reporting Driving fitness and threat disclosure
43 First Nations health and preventive care
First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention
44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases
Epidemiology, calculations, bias and surveillance
45 Neurological presentations
Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness
46 Musculoskeletal pain
Back, neck, bone and soft tissue pain
47 Eye presentations
Altered vision and retinal disease Red eye, ocular injury and discharge
48 Ear, nose, throat and oral health
Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis
49 Skin, hair and nails
Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities
50 Breast health and feeding
Breast lumps, discharge and breastfeeding problems
51 Sexual and reproductive presentations
Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction
52 Palliative care and carers
The dying patient, symptoms and carers
53 Eating disorders and personality care
Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care
54 Sleep presentations
Insomnia, snoring and daytime sleepiness
55 Poisoning, resuscitation and environmental emergencies
Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning
56 Communication, rights and professional practice
Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health
57 Genetics, research and donation
Genetic testing, research and organ donation
58 Travel, fever and outbreaks
Fever, travellers and outbreak response
Arthritis, autoimmune disease and geriatric care
Key Takeaways Explain This Topic AI
Crystals in joint fluid do not exclude concurrent septic arthritis.
Suspected giant cell arteritis requires prompt treatment to protect vision.
A 4AT score of at least 4 suggests delirium and needs clinical assessment.
Last updated: October 2026
Inflammatory Arthropathies & Crystal Diseases
Accurate differentiation between inflammatory synovitis, crystal-induced arthritis, and septic arthritis is essential to prevent permanent joint destruction.
Joint Fluid Aspiration Characteristics
Normal : Macroscopic Appearance: Clear, straw, viscous; Leucocyte Count ( cells/ μ L \text{cells/}\mu\text{L} cells/ μ L ): < 200 < 200 < 200 ; Neutrophils: < 25 % < 25\% < 25% ; Polarized Light Microscopy: No crystals
Osteoarthritis (Non-inflammatory) : Macroscopic Appearance: Clear, yellow, viscous; Leucocyte Count ( cells/ μ L \text{cells/}\mu\text{L} cells/ μ L ): 200 − 2 , 000 200 - 2,000 200 − 2 , 000 ; Neutrophils: < 25 % < 25\% < 25% ; Polarized Light Microscopy: No crystals
Rheumatoid / Inflammatory Arthritis : Macroscopic Appearance: Translucent/turbid, yellow; Leucocyte Count ( cells/ μ L \text{cells/}\mu\text{L} cells/ μ L ): 2 , 000 − 50 , 000 2,000 - 50,000 2 , 000 − 50 , 000 ; Neutrophils: 50 − 75 % 50 - 75\% 50 − 75% ; Polarized Light Microscopy: No crystals
Gout : Macroscopic Appearance: Turbid, milky; Leucocyte Count ( cells/ μ L \text{cells/}\mu\text{L} cells/ μ L ): 10 , 000 − 50 , 000 + 10,000 - 50,000+ 10 , 000 − 50 , 000 + ; Neutrophils: > 75 % > 75\% > 75% ; Polarized Light Microscopy: Needle-shaped, strongly negatively birefringent crystals (bright yellow parallel to axis)
Pseudogout (CPPD) : Macroscopic Appearance: Turbid, cloudy; Leucocyte Count ( cells/ μ L \text{cells/}\mu\text{L} cells/ μ L ): 10 , 000 − 50 , 000 + 10,000 - 50,000+ 10 , 000 − 50 , 000 + ; Neutrophils: > 75 % > 75\% > 75% ; Polarized Light Microscopy: Rhomboid-shaped, weakly positively birefringent crystals (bright blue parallel to axis)
Septic Arthritis : Macroscopic Appearance: Opaque, purulent, thick; Leucocyte Count ( cells/ μ L \text{cells/}\mu\text{L} cells/ μ L ): > 50 , 000 > 50,000 > 50 , 000 (often > 100 , 000 > 100,000 > 100 , 000 ); Neutrophils: > 90 % > 90\% > 90% ; Polarized Light Microscopy: Gram stain/culture may identify infection; negative results do not exclude it, and crystals may coexist
Clinical Profiles of Arthropathies
Rheumatoid Arthritis (RA):
Chronic, systemic autoimmune polyarthritis with predilection for small joints of the hands and feet: metacarpophalangeal (MCP), proximal interphalangeal (PIP), and metatarsophalangeal (MTP) joints, alongside wrists. Distal interphalangeal (DIP) joints and the thoracolumbar spine are characteristically spared .
Symptoms: Symmetrical joint pain, swelling, and early morning stiffness > 60 minutes > 60\text{ minutes} > 60 minutes that improves with physical activity.
Serology: Anti-cyclic citrullinated peptide (anti-CCP) antibodies are highly specific ( > 95 − 98 % > 95-98\% > 95 − 98% ) and predict aggressive erosive disease. Rheumatoid Factor (RF) is sensitive ( 70 − 80 % 70-80\% 70 − 80% ) but less specific.
Pharmacotherapy: Early introduction of disease-modifying antirheumatic drugs (DMARDs) is mandatory to prevent irreversible erosive joint destruction:
First-Line csDMARD: Methotrexate ( 10 − 25 mg 10 - 25\text{ mg} 10 − 25 mg once weekly) co-prescribed with folic acid ( 5 mg 5\text{ mg} 5 mg once weekly on a different day to reduce GI toxicity, stomatitis, and hepatic transaminitis). Baseline tests: full blood count, liver function tests, renal function, and chest X-ray. Regular FBC and LFT monitoring every 4-8 weeks is mandatory.
Biologic DMARDs: TNF-alpha inhibitors (adalimumab, infliximab, etanercept). Pre-treatment screening for latent tuberculosis (QuantiFERON-TB Gold or Mantoux test) , Hepatitis B, and Hepatitis C is mandatory prior to commencement to prevent fatal reactivation.
Gout:
Deposition of monosodium urate (MSU) crystals in joints following chronic hyperuricaemia. Characterized by sudden, excruciating monoarthritis, classically affecting the first metatarsophalangeal joint ( podagra ) in > 50 % > 50\% > 50% .
Acute Treatment: High-dose NSAIDs (naproxen, indomethacin), low-dose oral colchicine ( 1 mg 1\text{ mg} 1 mg stat, followed by 0.5 mg 0.5\text{ mg} 0.5 mg 1 hour later, then 0.5 mg 0.5\text{ mg} 0.5 mg bd; avoid old toxic regimens), or intra-articular/systemic corticosteroids.
Long-Term Urate-Lowering Therapy (ULT): Indicated for recurrent attacks ( ≥ 2 / year \ge 2/\text{year} ≥ 2/ year ), presence of tophi, radiological erosions, or renal calculi. First-line is allopurinol (xanthine oxidase inhibitor), started at 100 mg 100\text{ mg} 100 mg daily and titrated to target serum urate < 0.36 mmol/L < 0.36\text{ mmol/L} < 0.36 mmol/L ( < 0.30 mmol/L < 0.30\text{ mmol/L} < 0.30 mmol/L if tophi present). Mandatory rule: Co-prescribe prophylactic colchicine ( 0.5 mg 0.5\text{ mg} 0.5 mg daily) or an NSAID for the first 3 to 6 months of allopurinol initiation to prevent acute mobilization flares.
Pseudogout (Calcium Pyrophosphate Dihydrate [CPPD]):
Rhomboid, positively birefringent crystals in synovial fluid; predilection for large joints (knees, wrists). Plain radiographs demonstrate chondrocalcinosis (calcification of the articular cartilage or menisci). Associated with haemochromatosis, primary hyperparathyroidism, and hypomagnesaemia.
Septic Arthritis:
Medical and surgical emergency. Presents with an acutely warm, erythematous, swollen, exquisitely tender joint with severe restriction of both active and passive range of motion, accompanied by fever and systemic toxicity. Most commonly Staphylococcus aureus (including MRSA) or Neisseria gonorrhoeae in young adults.
Suspected septic arthritis: Aspirate and culture urgently, but do not delay antibiotics/resuscitation in sepsis or shock. A negative Gram stain, cell count below 50,000 or crystals cannot safely exclude infection. Obtain orthopaedic input and select antibiotics for the patient and local microbiology.
- Systemic Autoimmune Conditions: SLE & Giant Cell Arteritis
- Systemic Lupus Erythematosus (SLE)
Multisystem autoimmune disease driven by immune complex deposition affecting women of childbearing age ( 9 : 1 9:1 9 : 1 female-to-male ratio).
Manifestations: Malar 'butterfly' rash (sparing nasolabial folds), discoid lupus, photosensitivity, non-scarring alopecia, painless oral ulcers, non-erosive polyarthritis, serositis (pleurisy, pericarditis), lupus nephritis, and haematological cytopenias.
Serological Markers:
Anti-Nuclear Antibody (ANA): Sensitive ( > 95 % > 95\% > 95% ); ideal initial screening test; negative ANA virtually excludes active SLE.
Anti-double-stranded DNA (anti-dsDNA): Highly specific ( > 95 % > 95\% > 95% ); titres correlate with disease flares and active lupus nephritis .
Anti-Smith (anti-Sm): Highly specific for SLE.
Anti-Ro (SSA) and Anti-La (SSB): Associated with photosensitivity, secondary Sjögren syndrome, and neonatal lupus (causing congenital complete heart block in the infant).
Serum Complement (C3, C4): Depressed during active immune-complex consumption flares.
SLE treatment: Hydroxychloroquine is recommended for most patients unless contraindicated, with dose/risk-aware retinal surveillance. Higher-risk patients need earlier monitoring. Nephritis and other organ disease require rheumatology/nephrology assessment and phenotype-specific immunosuppression.
Giant Cell Arteritis (GCA / Temporal Arteritis)
Granulomatous large-vessel vasculitis affecting individuals > 50 years > 50\text{ years} > 50 years of age , strongly associated with Polymyalgia Rheumatica (PMR) (bilateral aching and morning stiffness in the shoulder and pelvic girdles).
Clinical Presentation:
- New-onset localized headache (predominantly temporal)
- Scalp tenderness (pain when combing hair or resting head on a pillow)
Jaw claudication (fatigue and cramping pain in masseter muscles while chewing food, highest specificity for GCA)
Visual symptoms: Amaurosis fugax, diplopia, or sudden painless unilateral visual loss caused by anterior ischaemic optic neuropathy (AION) due to posterior ciliary artery occlusion.
GCA investigations: ESR and CRP are often raised, but normal results do not exclude disease. Urgent ultrasound in an experienced service and/or biopsy support diagnosis; visual threat warrants immediate glucocorticoids and specialist care without awaiting tests.
Definitive Diagnosis: Temporal artery biopsy demonstrating transmural granulomatous inflammation with multinucleated giant cells and disruption of the internal elastic lamina. Because inflammation is segmental ('skip lesions'), a biopsy length of ≥ 1.5 − 2.0 cm \ge 1.5 - 2.0\text{ cm} ≥ 1.5 − 2.0 cm is required. Temporal artery duplex ultrasound showing a non-compressible hypoechoic wall oedema ('halo sign') is an excellent non-invasive adjunct.
Critical Emergency Rule: If Giant Cell Arteritis is suspected, commence immediate high-dose systemic corticosteroids (oral prednisolone 1 mg/kg/day, typically 50-60 mg daily, or intravenous methylprednisolone 500-1000 mg daily for 3 days if visual symptoms are present) prior to performing a temporal artery biopsy. Biopsy remains diagnostic for up to 1-2 weeks following steroid initiation, and delayed treatment risks permanent, irreversible bilateral blindness.
Comprehensive Geriatric Assessment (CGA)
The Comprehensive Geriatric Assessment is a multidisciplinary diagnostic process evaluating medical, psychological, and functional capabilities of frail older adults to coordinate integrated treatment plans.
1. Delirium: Identification and Management
Delirium is an acute, fluctuating neurocognitive syndrome characterized by disturbances in attention, awareness, and baseline cognition. It is categorized into hyperactive, hypoactive (most common, characterized by lethargy, reduced motor activity, and withdrawal; associated with worse prognosis), and mixed subtypes.
Delirium screening: 4AT at least 4 suggests delirium and requires clinical assessment for acute change and causes. CAM assesses acute/fluctuating course, inattention and either disorganised thinking or altered consciousness. Neither replaces a search for reversible illness.
- Acute onset and fluctuating course, AND
- Inattention, AND EITHER
- Disorganized thinking, OR
Altered level of consciousness.
Precipitating Factors: The 'PINCH ME' Mnemonic:
- P — Pain (inadequately controlled)
- I — Infection (urinary tract infection, pneumonia, cellulitis)
- N — Nutrition / Starvation
- C — Constipation / Urinary retention
- H — Hydration (dehydration) / Hypoxia
M — Medication (anticholinergics, benzodiazepines, opioids, polypharmacy) / Metabolic (electrolyte derangements)
E — Environment (room changes, sensory deprivation, sleep cycle disruption)
Delirium Management: First-line therapy is non-pharmacological and environmental : frequent verbal reorientation, presence of family members, ensuring sensory aids (glasses and hearing aids) are in place, single quiet room with natural daylight, visible clock/calendar, early mobilization, and avoiding physical restraints. Pharmacotherapy (low-dose oral haloperidol 0.25 − 0.5 mg 0.25 - 0.5\text{ mg} 0.25 − 0.5 mg or risperidone 0.25 − 0.5 mg 0.25 - 0.5\text{ mg} 0.25 − 0.5 mg ) is reserved strictly for severe distress or intractable agitation where the patient poses immediate danger to themselves or others, using the lowest effective dose for < 48 − 72 hours < 48-72\text{ hours} < 48 − 72 hours .
2. Falls Risk Assessment & Deprescribing
Falls Assessment: Multidisciplinary assessment includes history of falls, mobility testing using the Timed Up and Go (TUG) test (time > 12 seconds > 12\text{ seconds} > 12 seconds indicates heightened fall risk), environmental hazard inspection, vision screening, and targeted physical therapy.
Deprescribing & Beers Criteria: Reviewing and ceasing potentially inappropriate medications in older adults:
- Anticholinergics and sedating antihistamines (urinary retention, delirium, cognitive decline)
- Benzodiazepines and Z-drugs (falls, hip fractures, motor vehicle accidents)
- Tertiary tricyclic antidepressants (postural hypotension, cardiac conduction delay)
Non-steroidal anti-inflammatory drugs (gastric ulceration, worsening renal function, heart failure decompensation)
Antihypertensives in patients with severe orthostatic hypotension (fall risk)
Frailty Syndrome: Characterized by diminished physiological reserve across multiple organ systems. Assessed using the Fried Frailty Phenotype (unintentional weight loss > 4.5 kg > 4.5\text{ kg} > 4.5 kg in 1 year, exhaustion, weak grip strength, slow walking speed, low physical activity; ≥ 3 \ge 3 ≥ 3 criteria confirms frailty).
Primary references (checked 7 October 2026): RACGP thrombocytopenia assessment .